Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Financing Activities: 2015-2024

Historic Cash from Financing Activities for Apellis Pharmaceuticals (APLS) over the last 10 years, with Dec 2024 value amounting to $149.2 million.

  • Apellis Pharmaceuticals' Cash from Financing Activities fell 68.80% to $793,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 97.57%. This contributed to the annual value of $149.2 million for FY2024, which is 62.17% down from last year.
  • According to the latest figures from FY2024, Apellis Pharmaceuticals' Cash from Financing Activities is $149.2 million, which was down 62.17% from $394.5 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Cash from Financing Activities ranged from a high of $692.2 million in FY2020 and a low of $149.2 million during FY2024.
  • Its 3-year average for Cash from Financing Activities is $303.1 million, with a median of $365.7 million in 2022.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first spiked by 78.15% in 2020, then crashed by 62.17% in 2024.
  • Apellis Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $692.2 million in 2020, then slumped by 43.33% to $392.2 million in 2021, then declined by 6.78% to $365.7 million in 2022, then rose by 7.89% to $394.5 million in 2023, then crashed by 62.17% to $149.2 million in 2024.